Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial

• Published in: Blood research Vol. 52; no. 3; pp. 200 - 206
• Main Authors: Seo, Jeongkuk, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Lee, Jae Hoon, Hong, Jun Shik, Lee, Gyeong-Won, Oh, Sung Yong, Lee, Ji-Hyun, Yoon, Dok Hyun, Lee, Won-Sik, Kim, Hyo Jung, Kwak, Jae-Yong, Kang, Hye Jin, Jo, Jae-Cheol, Park, Yong, Lee, Ho Sup, Kim, Hyo-Jin, Suh, Cheolwon
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 01.09.2017; 대한혈액학회
• Subjects: Original; 병리학; Prognosis; R-CVP; Marginal zone lymphoma; PLR
• ISSN: 2287-979X; 2288-0011
• DOI: 10.5045/br.2017.52.3.200

Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. Between August 2006 and June 2013, patients with newly diagnosed stage III and IV MZL treated with R-CVP as a first-line therapy from 15 institutions were retrospectively analyzed. Patients' clinical and laboratory data at diagnosis were collected by review of medical records. A total of 80 patients were analyzed. Bone marrow involvement was observed in 30% cases. Twelve patients (15%) had nodal MZL, and 41.3% patients exhibited multiple mucosa-associated lymphoma tissue sites. Overall response rate was 91.3%, including 73.8% achieving complete response. Advanced MZL patients treated with R-CVP showed a 3-year progression-free survival (PFS) rate of 69.6%. Prognostic markers significantly affecting PFS in univariate analysis were platelet to lymphocyte ratio (PLR, <95 vs. ≥95, =0.014), serum albumin (≤3.9 vs. >3.9 g/dL, =0.008), and the International Prognostic Index (IPI) score (1 vs. 2-4, =0.032). In multivariate analysis, only PLR (<95 vs. ≥95, HR 0.367, 95% CI, 0.139-0.971, =0.043) was an independent risk factor for PFS. PLR ≥95 at diagnosis is an independent prognostic marker for PFS in advanced stage MZL patients treated with R-CVP. This marker may aid clinicians in predicting the response to R-CVP chemotherapy in stage III and IV MZL patients.